Metraipolis › archive › dc_9efe0fb01fea

Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney… — Europe PMC PMID:40608494

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40608494
DOI: 10.1093/ndt/gfaf114
License (as archived): solo-consultazione
Archived: 2026-11-09T16:22:49.589Z
SHA-256 of the archived text: 3d9eba5afa548964d661f5a713c3d6f726c1623e3023779bc55c5bc68d877272
Stable URL of this page: https://metraipolis.com/documento/dc_9efe0fb01fea

How to cite

Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney… — Europe PMC PMID:40608494 — Europe PMC (en), https://europepmc.org/article/MED/40608494 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9efe0fb01fea (Metraipolis archive dc_9efe0fb01fea, sha256 3d9eba5afa548964d661f5a713c3d6f726c1623e3023779bc55c5bc68d877272)

BibTeX

@misc{dc9efe0fb01fea,
  title = {Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney… — Europe PMC PMID:40608494},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40608494},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9efe0fb01fea; sha256 3d9eba5afa548964d661f5a713c3d6f726c1623e3023779bc55c5bc68d877272},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40608494. Agents can read the archived copy with the MCP tool read_document.